TSE:4530Pharmaceuticals
Hisamitsu Pharmaceutical (TSE:4530) Margin Decline Tests Bullish Premium Valuation Narratives
Hisamitsu Pharmaceutical (TSE:4530) has reported its FY 2026 results with fourth quarter revenue of ¥48.5b and basic EPS of ¥103.57, alongside trailing 12 month revenue of ¥163.0b and EPS of ¥268.55 that frame the latest quarter in a wider context. The company has seen revenue move from ¥156.0b to ¥163.0b on a trailing 12 month basis, while trailing EPS shifted from ¥295.58 to ¥268.55, setting up a picture where top line progress sits alongside softer earnings and margins that investors may...